COVID-19 Vaccines in Children

Area of Science:

• Public Health
• Infectious Diseases
• Vaccinology

Background:

• The COVID-19 pandemic significantly impacted global health across all age groups.
• While severe outcomes were more common in adults, the effects on children became a focus.
• Genomic surveillance identified SARS-CoV-2 XBB sublineages as dominant variants by September 2023.

Purpose of the Study:

• To update COVID-19 vaccination recommendations based on current circulating SARS-CoV-2 variants.
• To ensure continued protection against evolving strains of the virus, particularly in pediatric populations.

Main Methods:

• Ongoing genomic surveillance of SARS-CoV-2 specimens.
• Analysis of circulating variant data to inform vaccine strain selection.
• Review of vaccine efficacy and safety data for pediatric populations.

Main Results:

• SARS-CoV-2 XBB sublineages represented over 99% of sequenced specimens in the US as of September 2023.
• Vaccination recommendations were updated to a 2023-2024 Omicron-XBB.1.5-adapted monovalent vaccine.
• COVID-19 vaccines demonstrated safety and efficacy in preventing illness and severe outcomes in children and adolescents.

Conclusions:

• The updated monovalent COVID-19 vaccine provides heightened protection against current XBB-sublineage variants.
• COVID-19 vaccination remains a critical tool for protecting children and adolescents from severe disease.
• Continued monitoring and adaptation of vaccines are essential for pandemic control.